223 related articles for article (PubMed ID: 30096444)
1. Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin.
Zou L; Ding W; Zhang Y; Cheng S; Li F; Ruan R; Wei P; Qiu B
Biomaterials; 2018 Nov; 182():1-12. PubMed ID: 30096444
[TBL] [Abstract][Full Text] [Related]
2. Enhanced transdermal efficiency of curcumin-loaded peptide-modified liposomes for highly effective antipsoriatic therapy.
Yu F; Zhang Y; Yang C; Li F; Qiu B; Ding W
J Mater Chem B; 2021 Jun; 9(24):4846-4856. PubMed ID: 34047333
[TBL] [Abstract][Full Text] [Related]
3. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
Ahmed KS; Shan X; Mao J; Qiu L; Chen J
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
[TBL] [Abstract][Full Text] [Related]
4. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Chisholm JC; Suvada J; Dunkel IJ; Casanova M; Zhang W; Ritchie N; Choi Y; Park J; Das Thakur M; Simko S; Wan Rachel Tam N; Ferrari A
Pediatr Blood Cancer; 2018 May; 65(5):e26947. PubMed ID: 29350463
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib in Chinese patients with BRAF
Si L; Zhang X; Xu Z; Jiang Q; Bu L; Wang X; Mao L; Zhang W; Richie N; Guo J
BMC Cancer; 2018 May; 18(1):520. PubMed ID: 29724167
[TBL] [Abstract][Full Text] [Related]
6. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
[TBL] [Abstract][Full Text] [Related]
7. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas.
Hwang TL; Lee WR; Hua SC; Fang JY
J Dermatol Sci; 2007 Apr; 46(1):11-20. PubMed ID: 17267180
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Transdermal Peptide-Modified Flexible Liposomes for Efficient Percutaneous Delivery of Chrysomycin A to Treat Subcutaneous Melanoma and Intradermal MRSA Infection.
Cai Y; Chu Y; Gong Y; Hong Y; Song F; Wang H; Zhang H; Sun X
Adv Healthc Mater; 2023 Oct; 12(26):e2300881. PubMed ID: 37267625
[TBL] [Abstract][Full Text] [Related]
11. The positive correlation between drug addiction and drug dosage in vemurafenib-resistant melanoma cells is underpinned by activation of ERK1/2-FRA-1 pathway.
Rao M; Shi B; Yuan Y; Wang Y; Chen Y; Liu X; Li X; Zhang M; Liu X; Sun X
Anticancer Drugs; 2020 Nov; 31(10):1026-1037. PubMed ID: 32868647
[TBL] [Abstract][Full Text] [Related]
12. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
13. Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer.
Xia T; He Q; Shi K; Wang Y; Yu Q; Zhang L; Zhang Q; Gao H; Ma L; Liu J
Pharm Dev Technol; 2018 Jan; 23(1):13-21. PubMed ID: 27884084
[TBL] [Abstract][Full Text] [Related]
14. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
Lin C; Zhang X; Chen H; Bian Z; Zhang G; Riaz MK; Tyagi D; Lin G; Zhang Y; Wang J; Lu A; Yang Z
Drug Deliv; 2018 Nov; 25(1):256-266. PubMed ID: 29334814
[TBL] [Abstract][Full Text] [Related]
15. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.
Capone E; Lamolinara A; D'Agostino D; Rossi C; De Laurenzi V; Iezzi M; Iacobelli S; Sala G
J Control Release; 2018 May; 277():48-56. PubMed ID: 29550398
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
17. Vitamin C at high concentrations induces cytotoxicity in malignant melanoma but promotes tumor growth at low concentrations.
Yang G; Yan Y; Ma Y; Yang Y
Mol Carcinog; 2017 Aug; 56(8):1965-1976. PubMed ID: 28370562
[TBL] [Abstract][Full Text] [Related]
18. Oestrogen receptor-mediated liposomal drug delivery for treating melanoma.
Ganguly A; Rachamalla HKR; Bhattacharya D; Bhamidipati K; Pal A; Gora Ravuri H; Chakravarty S; Adhikari SS; Banerjee R
J Drug Target; 2018; 26(5-6):481-493. PubMed ID: 29376759
[TBL] [Abstract][Full Text] [Related]
19. Transdermal delivery of brucine-encapsulated liposomes significantly enhances anti-tumor outcomes in treating triple-negative breast cancer.
Wu M; Hu Y; Xu M; Fu L; Li C; Wu J; Sun X; Wang W; Wang S; Wang T; Ding W; Li P
Biomater Adv; 2023 Oct; 153():213566. PubMed ID: 37536027
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
